Somewhat Positive Media Coverage Somewhat Unlikely to Affect AnaptysBio (ANAB) Stock Price
Media coverage about AnaptysBio (NASDAQ:ANAB) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AnaptysBio earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.0493359191972 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
ANAB has been the subject of a number of recent research reports. Wedbush reissued a “positive” rating and issued a $82.00 target price (up previously from $75.00) on shares of AnaptysBio in a research report on Tuesday, November 7th. Jefferies Group initiated coverage on shares of AnaptysBio in a research report on Thursday, November 9th. They set a “buy” rating and a $101.00 price objective for the company. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price objective for the company in a research report on Friday, November 10th. SunTrust Banks initiated coverage on shares of AnaptysBio in a research report on Wednesday, November 15th. They set a “buy” rating and a $115.00 price objective for the company. Finally, Royal Bank of Canada upped their price objective on shares of AnaptysBio to $108.00 and gave the stock an “outperform” rating in a research report on Monday, December 18th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $101.89.
Shares of AnaptysBio (NASDAQ ANAB) opened at $107.29 on Tuesday. AnaptysBio has a 52-week low of $18.15 and a 52-week high of $126.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77. The firm has a market cap of $2,500.00 and a PE ratio of -71.05.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.